Expertise in
20
conditions

Dr. Daniel Y. Danso

Hematology
MyMichigan Home Care
4500 Campus Ridge Dr, 
Midland, MI 
Accepting New Patients
Expertise in
20
conditions
MyMichigan Home Care
4500 Campus Ridge Dr, 
Midland, MI 

Overview

Daniel Danso is a Hematologist practicing medicine in Midland, Michigan.

Dr. Danso is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, ALK-Positive Non-Small Cell Lung Cancer, Non-Hodgkin Lymphoma, and Gastric Lymphoma.

He is actively involved in clinical research, participating in 5 clinical trials. Dr. Danso is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MI

Hospital Affiliations

Mymichigan Medical Center Gladwin
Mymichigan Medical Center Clare
Mymichigan Medical Center Midland
Mymichigan Medical Center Alpena

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

MyMichigan Home Care
4500 Campus Ridge Dr, Midland, MI 48640

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 4 Less Clinical Trials
Similar Doctors
Expertise in
30
conditions
Dr. John C. Hughes
Hematology | Oncology
Expertise in
30
conditions
Dr. John C. Hughes
Hematology | Oncology
Referral may be required

Covenant Healthcare

1447 N Harrison St, 
Saginaw, MI 
 (21.1 miles away)
989-583-5060
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hughes is a Hematologist and an Oncologist practicing medicine in Saginaw, Michigan. Dr. Hughes is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration. Dr. Hughes is currently accepting new patients.

Expertise in
43
conditions
Dr. Ronald H. Kawauchi
Hematology | Oncology
Expertise in
43
conditions
Dr. Ronald H. Kawauchi
Hematology | Oncology
Referral may be required

Office

721 N Shiawassee St, 
Owosso, MI 
 (44.1 miles away)
989-729-4673
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ronald Kawauchi is a Hematologist and an Oncologist practicing medicine in Owosso, Michigan. Dr. Kawauchi is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Myelodysplastic Syndrome (MDS). Dr. Kawauchi is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

McLaren Bay Region

1900 Columbus Ave, 
Bay City, MI 
 (19.9 miles away)
989-894-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sharon Levandowski is a Hematologist practicing medicine in Bay City, Michigan. Dr. Levandowski is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Gastroesophageal Junction Cancer, Anemia, Muscle Invasive Bladder Cancer, Pancreatic Ductal Adenocarcinoma, and Bone Marrow Aspiration. Dr. Levandowski is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel Y. Danso

How do I make an appointment with Dr. Daniel Y. Danso?

You can book an appointment with Dr. Daniel Y. Danso by calling their office at 989-839-6188. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Y. Danso a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Y. Danso is classified as an Advanced expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Y. Danso specialize in?

While Dr. Daniel Y. Danso is a Hematology, they have specific expertise in Multiple Myeloma, ALK-Positive Non-Small Cell Lung Cancer, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel Y. Danso accept my insurance?

Dr. Daniel Y. Danso accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 989-839-6188 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Danso's expertise for a condition
ConditionClose
      View All 20 Advanced Conditions
      View All 44 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile